NewAmsterdam Pharma Awaits EMA, MHRA, and Swissmedic Decisions on Obicetrapib in H2 2026

Regulatory affairs teams managing multi-jurisdictional cardiovascular submissions should note that NewAmsterdam Pharma is tracking concurrent approval decisions from the EMA, UK MHRA, and Swiss Swissmedic on obicetrapib and its fixed-dose combination with ezetimibe, with all three decisions expected in the second half of 2026. Conditional on those outcomes, commercial partner Menarini is positioned for potential launches in Germany and the UK as early as Q4 2026.

The parallel review timeline across three distinct regulatory jurisdictions reflects the coordination demands that cardiovascular drug programmes increasingly face post-ICH Q10 alignment. Each agency operates under its own procedural clock, and a staggered or misaligned decision sequence could compress Menarini's launch window or require market-specific labelling adjustments ahead of the Q4 target.

On the clinical side, NewAmsterdam completed enrollment in the REMBRANDT Phase 3 trial and confirmed a PREVAIL interim analysis for Q4 2026, with results expected in Q1 2027. The PREVAIL decision to conduct an interim analysis follows a blinded review showing a Year 1-to-Year 2 overall MACE event rate lower than anticipated, meeting the threshold for the minimum 2.5-year follow-up required to trigger the analysis. Topline data from the RUBENS Phase 3 trial are also expected by year-end 2026.

New analyses from the pivotal Phase 3 BROADWAY and BROOKLYN trials, presented at the American College of Cardiology Annual Scientific Session in March 2026 and simultaneously published in the American Journal of Preventive Cardiology, extended the obicetrapib safety dataset. A pooled analysis showed obicetrapib 10 mg was associated with a slower annualised decline in estimated glomerular filtration rate (eGFR) compared with placebo (-0.41 vs. -1.08 mL/min/1.73 m²), alongside nominally fewer composite renal events over 12 months. For QA and regulatory leads, these post-hoc renal and metabolic signal analyses are likely to feature in agency queries across all three submissions.

NewAmsterdam reported $707.3 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing the runway to sustain three concurrent Phase 3 programmes through anticipated readouts.

The Q4 2026 PREVAIL interim analysis will serve as the next measurable checkpoint for both the clinical programme and the broader regulatory narrative NewAmsterdam is building across European markets.

Source: NewAmsterdam Pharma via GlobeNewswire, 7 May 2026. Management hosted a PREVAIL update call at 8:00 AM ET on the same date.